Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04986865 | A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas(PROBE) | terminated | Phase 1 | 31 | Antengene Biologics LimitedINDUSTRY | 2 | Jun 9, 2025 | clinicaltrials |
| NCT02419495 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | terminated | Phase 1 | 221 | M.D. Anderson Cancer CenterOTHER | 1 |
| Jun 4, 2025 |
| clinicaltrials |
| NCT06535009 | Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors | terminated | Phase 1 | 25 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 4, 2025 | clinicaltrials |
| NCT04405778 | A Study of TAK-102 in Adult With Previously-Treated Solid Tumors | terminated | Phase 1 | 12 | TakedaINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
| NCT04442126 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 52 | Numab Therapeutics AGINDUSTRY | 3 | May 23, 2025 | clinicaltrials |
| NCT05192174 | Study of NIB101 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 3 | Noile-Immune Biotech, IncINDUSTRY | 1 | May 23, 2025 | clinicaltrials |
| NCT05389462 | A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors | terminated | Phase 1 | 128 | ADC Therapeutics S.A.INDUSTRY | 4 | May 22, 2025 | clinicaltrials |
| NCT04642365 | A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors. | terminated | Phase 1 | 49 | Hoffmann-La RocheINDUSTRY | 6 | May 21, 2025 | clinicaltrials |
| NCT04927663 | 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression | terminated | Phase 1 | 2 | Rahul AggarwalOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT04579757 | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 87 | HutchmedINDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT05242822 | A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations | terminated | Phase 1 | 54 | Kinnate BiopharmaINDUSTRY | 6 | May 7, 2025 | clinicaltrials |
| NCT05388435 | Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients | terminated | Phase 1 / Phase 2 | 15 | SK Life Science, Inc.INDUSTRY | 1 | May 4, 2025 | clinicaltrials |
| NCT05494762 | Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors | terminated | Phase 1 | 55 | BeiGeneINDUSTRY | 2 | May 1, 2025 | clinicaltrials |
| NCT05757492 | Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors | terminated | Phase 1 | 22 | Coherus Oncology, Inc.INDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT05840510 | Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19) | terminated | Phase 1 | 6 | Mirati Therapeutics Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors(RAPTOR) | terminated | Phase 1 | 27 | Turnstone Biologics, Corp.INDUSTRY | 3 | Apr 23, 2025 | clinicaltrials |
| NCT05435339 | A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy | terminated | Phase 1 / Phase 2 | 31 | GenmabINDUSTRY | 2 | Apr 22, 2025 | clinicaltrials |
| NCT04209465 | A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.(MasterKey-01) | terminated | Phase 1 | 91 | Black Diamond Therapeutics, Inc.INDUSTRY | 4 | Apr 17, 2025 | clinicaltrials |
| NCT04013217 | Evaluate Eribulin ORA in Subjects With Solid Tumors | terminated | Phase 1 | 10 | Health Hope PharmaINDUSTRY | 1 | Apr 13, 2025 | clinicaltrials |
| NCT03975387 | Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53 | terminated | Phase 1 | 106 | Taiho Oncology, Inc.INDUSTRY | 1 | Apr 9, 2025 | clinicaltrials |
| NCT03690869 | REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma | terminated | Phase 1 / Phase 2 | 57 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 8, 2025 | clinicaltrials |
| NCT05904236 | Safety and Tolerability of Intravenous Administration of ICVB-1042(ICVB-1042) | terminated | Phase 1 | 17 | IconOVir BioINDUSTRY | 1 | Apr 8, 2025 | clinicaltrials |
| NCT05737706 | Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | terminated | Phase 1 | 63 | Mirati Therapeutics Inc.INDUSTRY | 1 | Apr 6, 2025 | clinicaltrials |
| NCT04553692 | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers | terminated | Phase 1 | 272 | IGM Biosciences, Inc.INDUSTRY | 5 | Mar 28, 2025 | clinicaltrials |
| NCT04084366 | Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 44 | OBI Pharma, IncINDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT04239040 | GVAX Plus Checkpoint Blockade in Neuroblastoma | terminated | Phase 1 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT04101357 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 | terminated | Phase 1 / Phase 2 | 54 | BioNTech SEINDUSTRY | 4 | Mar 18, 2025 | clinicaltrials |
| NCT05543629 | A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 36 | Bristol-Myers SquibbINDUSTRY | 5 | Mar 18, 2025 | clinicaltrials |
| NCT05559541 | Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 33 | AkesoINDUSTRY | 1 | Feb 19, 2025 | clinicaltrials |
| NCT04718675 | A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC) | terminated | Phase 1 / Phase 2 | 135 | Kronos BioINDUSTRY | 3 | Feb 17, 2025 | clinicaltrials |
| NCT05135650 | Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study | terminated | Phase 1 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT05497453 | A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene(MYCHELANGELO I) | terminated | Phase 1 / Phase 2 | 24 | Omega TherapeuticsINDUSTRY | 5 | Feb 3, 2025 | clinicaltrials |
| NCT05098405 | First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors | terminated | Phase 1 | 46 | Molecular Partners AGINDUSTRY | 2 | Jan 30, 2025 | clinicaltrials |
| NCT05601219 | A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors | terminated | Phase 1 | 46 | Adanate, IncINDUSTRY | 1 | Jan 28, 2025 | clinicaltrials |
| NCT04074759 | FPT155 in Patients With Advanced Solid Tumors(FPT155-001) | terminated | Phase 1 | 80 | Five Prime Therapeutics, Inc.INDUSTRY | 2 | Jan 23, 2025 | clinicaltrials |
| NCT03854227 | A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors | terminated | Phase 1 | 54 | PfizerINDUSTRY | 1 | Jan 13, 2025 | clinicaltrials |
| NCT05382936 | Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 20 | Stemline Therapeutics, Inc.INDUSTRY | 1 | Jan 9, 2025 | clinicaltrials |
| NCT02671890 | Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer | terminated | Phase 1 | 16 | Mayo ClinicOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | terminated | Phase 1 / Phase 2 | 15 | Aminex Therapeutics, Inc.INDUSTRY | 2 | Dec 24, 2024 | clinicaltrials |
| NCT06524804 | A Phase Ib/II Study of BY101298 , an Oral DNA-PK Inhibitor, Combined with Radiotherapy in Patients with Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 60 | Chengdu Baiyu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT04528836 | First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 72 | Navire Pharma Inc., a BridgeBio companyINDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT05375084 | SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation | terminated | Phase 1 | 21 | Navire Pharma Inc., a BridgeBio companyINDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT05480865 | SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation(Argonaut) | terminated | Phase 1 | 28 | Navire Pharma Inc., a BridgeBio companyINDUSTRY | 7 | Dec 12, 2024 | clinicaltrials |
| NCT04939701 | Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants | terminated | Phase 1 / Phase 2 | 16 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT05831995 | Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors. | terminated | Phase 1 | 12 | ABM Therapeutics CorporationINDUSTRY | 1 | Dec 6, 2024 | clinicaltrials |
| NCT06290388 | Study of 23ME-01473 in Patients With Advanced Solid Malignancies | terminated | Phase 1 / Phase 2 | 5 | 23andMe, Inc.INDUSTRY | 1 | Dec 4, 2024 | clinicaltrials |
| NCT03387917 | TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors | terminated | Phase 1 | 12 | Swiss Cancer InstituteOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT05501912 | A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors | terminated | Phase 1 | 20 | ABM Therapeutics Shanghai Company LimitedINDUSTRY | 1 | Nov 29, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Jun 9, 2025source: clinicaltrials